Wechselwirkungen · Tepadina
TEPADINA 200 mg powder and solvent for solution for infusion TEPADINA 400 mg powder and solvent for solution for infusion · Abschnitt 4.5 · PDF-Seite 25
HOS-210425 · Präparat HOS-154509
Interaction common to all cytotoxics Due to the increase of thrombotic risk in case of malignancy, the use of anticoagulative treatment is frequent. The high intra-individual variability of the coagulation state during malignancy and the potential interaction between oral anticoagulants and anticancer chemotherapy require, if it is decided to treat the patient with oral anticoagulants, to increase the frequency of the INR (International Normalised Ratio) monitoring.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-24T14:00:00Z · SHA-256 42c8bab87a55159cb982d55f577a064273549ce149f75b75dbf4d5650be413bc · Passage d97a65431dc80f9e787863a57445f2623feab5e0bc41ec6354511b274a7e66f1 · Zeichen 3346–3816 im Abschnitt